# A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

> **NCT01886820** · PHASE3 · UNKNOWN · sponsor: **Navidea Biopharmaceuticals** · enrollment: 290 (estimated)

## Conditions studied

- Dementia
- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]NAV4694

## Key facts

- **NCT ID:** NCT01886820
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2018-06
- **Final completion:** 2018-09
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01886820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01886820, "A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01886820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*